Literature DB >> 32275896

Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia.

Armin Rashidi1, Daniel J Weisdorf2.   

Abstract

Despite advances in antimicrobial treatments, infection remains a common complication of intensive chemotherapy in patients with acute leukemia. It has become progressively apparent that the current antimicrobial focus has shortcomings that result from disruption of the commensal microbial communities of the gut. These effects, collectively known as dysbiosis, have been increasingly associated worldwide with growing complications such as Clostridioides difficile infection, systemic infections, and antibiotic resistance. A revision of the current practice is overdue. Several innovative concepts have been proposed and tested in animal models and humans, with the overarching goal of preventing damage to the microbiota and facilitating its recovery. In this review, we discuss these approaches, examine critical knowledge gaps, and explore how they may be filled in future research.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute leukemia; Chemotherapy; Dysbiosis; Microbiota; Transplantation

Mesh:

Substances:

Year:  2020        PMID: 32275896      PMCID: PMC7605891          DOI: 10.1016/j.trsl.2020.03.011

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  118 in total

Review 1.  Commensal host-bacterial relationships in the gut.

Authors:  L V Hooper; J I Gordon
Journal:  Science       Date:  2001-05-11       Impact factor: 47.728

2.  Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation.

Authors:  Armin Rashidi; Thomas Kaiser; Carolyn Graiziger; Shernan G Holtan; Tauseef Ur Rehman; Daniel J Weisdorf; Gary M Dunny; Alexander Khoruts; Christopher Staley
Journal:  Cancer       Date:  2019-12-24       Impact factor: 6.860

3.  Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile.

Authors:  Mary C Rea; Clarissa S Sit; Evelyn Clayton; Paula M O'Connor; Randy M Whittal; Jing Zheng; John C Vederas; R Paul Ross; Colin Hill
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-30       Impact factor: 11.205

4.  Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults.

Authors:  E J Bow; R Loewen; M S Cheang; T B Shore; M Rubinger; B Schacter
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

5.  Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant.

Authors:  Ying Taur; Katharine Coyte; Jonas Schluter; Elizabeth Robilotti; Cesar Figueroa; Mergim Gjonbalaj; Eric R Littmann; Lilan Ling; Liza Miller; Yangtsho Gyaltshen; Emily Fontana; Sejal Morjaria; Boglarka Gyurkocza; Miguel-Angel Perales; Hugo Castro-Malaspina; Roni Tamari; Doris Ponce; Guenther Koehne; Juliet Barker; Ann Jakubowski; Esperanza Papadopoulos; Parastoo Dahi; Craig Sauter; Brian Shaffer; James W Young; Jonathan Peled; Richard C Meagher; Robert R Jenq; Marcel R M van den Brink; Sergio A Giralt; Eric G Pamer; Joao B Xavier
Journal:  Sci Transl Med       Date:  2018-09-26       Impact factor: 17.956

6.  Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits.

Authors:  Katharina Brandl; George Plitas; Coralia N Mihu; Carles Ubeda; Ting Jia; Martin Fleisher; Bernd Schnabl; Ronald P DeMatteo; Eric G Pamer
Journal:  Nature       Date:  2008-08-24       Impact factor: 49.962

7.  Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.

Authors:  Sarah Alexander; Brian T Fisher; Aditya H Gaur; Christopher C Dvorak; Doojduen Villa Luna; Ha Dang; Lu Chen; Michael Green; Michael L Nieder; Beth Fisher; L Charles Bailey; John Wiernikowski; Lillian Sung
Journal:  JAMA       Date:  2018-09-11       Impact factor: 56.272

8.  Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection.

Authors:  Alexa Weingarden; Antonio González; Yoshiki Vázquez-Baeza; Sophie Weiss; Gregory Humphry; Donna Berg-Lyons; Dan Knights; Tatsuya Unno; Aleh Bobr; Johnthomas Kang; Alexander Khoruts; Rob Knight; Michael J Sadowsky
Journal:  Microbiome       Date:  2015-03-30       Impact factor: 14.650

9.  Bacteriophages from ExPEC Reservoirs Kill Pandemic Multidrug-Resistant Strains of Clonal Group ST131 in Animal Models of Bacteremia.

Authors:  Sabrina I Green; Jason T Kaelber; Li Ma; Barbara W Trautner; Robert F Ramig; Anthony W Maresso
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

10.  Protection of the Human Gut Microbiome From Antibiotics.

Authors:  Jean de Gunzburg; Amine Ghozlane; Annie Ducher; Emmanuelle Le Chatelier; Xavier Duval; Etienne Ruppé; Laurence Armand-Lefevre; Frédérique Sablier-Gallis; Charles Burdet; Loubna Alavoine; Elisabeth Chachaty; Violaine Augustin; Marina Varastet; Florence Levenez; Sean Kennedy; Nicolas Pons; France Mentré; Antoine Andremont
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

View more
  2 in total

Review 1.  Opportunities and Challenges for Gut Microbiota in Acute Leukemia.

Authors:  Tao Ma; Yan Chen; Li-Juan Li; Lian-Sheng Zhang
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

2.  Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.

Authors:  Hong Luo; Yanping Xiao; Yaping Hang; Yanhui Chen; Hongying Zhu; Xueyao Fang; Xingwei Cao; Shan Zou; Xiaoyan Hu; Jianqiu Xiong; Qiaoshi Zhong; Longhua Hu
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-09-06       Impact factor: 3.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.